Meningococcal Meningitis (DBCOND0034253)

Identifiers

Synonyms
Meningitis, Meningococcal / Meningitis meningococcal / Meningococcal meningitis / Neisseria meningitides meningitis / Meningococcal meningitis (disorder)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Acetyl sulfisoxazole
Acute, recurrent or chronic urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) due to susceptible organisms (usually Escherichia coli, Klebsiella-Enterobacter, staphylococcus, Proteus mirabilis and, less frequently, Proteus vulgaris) in the...
Benzylpenicillin
A penicillin used for the treatment of infections caused by gram-positive cocci, in particular streptococcal infections. This form of penicillin is typically used in intravenous or long-acting injectable formulations due to poor oral absorption.
Sulfadiazine
A sulfonamide antibiotic used in a variety of infections, such as urinary tract infections, trachoma, and chancroid.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT02591290
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjectsprevention4completed
NCT00355121
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®prevention2completed
NCT00937521
Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old InfantsNo drug interventionsprevention2completed
NCT00667602
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlersprevention3completed
NCT01423084
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 YearsNo drug interventionsprevention3completed
NCT01466387
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adultsprevention3completed
NCT00474487
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy AdultsNo drug interventionsprevention3completed
NCT02842853
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccineprevention3completed
NCT00384397
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlersprevention3completed
NCT00856297
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccineprevention3completed
NCT01192997
Comparison of Two Meningococcal ACWY Conjugate Vaccinesprevention2 / 3completed
NCT02500511
Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT00310856
Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)prevention2completed
NCT01210885
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in AdolescentsNo drug interventionsprevention2completed
NCT01148017
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccineprevention3completed
NCT00944034
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12No drug interventionsprevention2 / 3completed
NCT01367158
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccinesprevention2completed
NCT01453348
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccineprevention3completed
NCT02842866
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Olderprevention3completed
NCT02864927
Postmarketing Surveillance Study for Use of Menactra® in the Republic of Koreaprevention4completed
NCT00518180
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In AdolescentsNo drug interventionsprevention3completed
NCT01434680
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlersprevention2completed
NCT01424644
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescentsprevention4completed
NCT02699840
Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian FederationNot AvailableNot Availablecompleted
NCT00994695
Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 VaccineNo drug interventionsprevention2completed
NCT06226714
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Oldsprevention3active_not_recruiting
NCT01339923
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 YearsNo drug interventionsprevention3completed
NCT01717638
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1No drug interventionsprevention3completed
NCT01239043
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccinationprevention2completed
NCT01897402
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate VaccineNo drug interventionsprevention2completed
NCT02633787
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earliertreatment4completed
NCT06131554
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Yearsprevention3active_not_recruiting
NCT01478347
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk AdultsNo drug interventionsprevention3completed
NCT01274897
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaNo drug interventionsprevention3completed
NCT02955797
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlersprevention3completed
NCT02919293
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of AgeNo drug interventionsprevention1 / 2unknown_status
NCT06337071
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate VaccineNo drug interventionsprevention2not_yet_recruiting
NCT01214837
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of LifeNo drug interventionsprevention3completed
NCT00450437
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and AdultsNo drug interventionsprevention3completed
NCT02481232
A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate VaccineNo drug interventionsprevention1unknown_status
NCT01018732
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWYNo drug interventionsprevention2completed
NCT01482052
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for MeningitisNo drug interventionsprevention1completed
NCT02752906
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccineprevention3completed
NCT00874549
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Yearsprevention1 / 2completed
NCT01519713
Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjectsprevention3completed
NCT01894919
Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28prevention3completed
NCT00310817
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.No drug interventionsprevention2completed
NCT01148524
Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10No drug interventionsprevention2 / 3completed
NCT03205358
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlersprevention2completed
NCT00483574
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlersprevention3completed
NCT01732627
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderNo drug interventionsprevention2completed
NCT02199691
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescentsprevention2completed
NCT00422292
Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlersprevention3completed
NCT00329901
Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Yearsprevention3completed
NCT02640404
Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnamprevention2completed
NCT03964012
Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)prevention3completed
NCT03077438
Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Yearsprevention3completed
NCT01352793
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 YearsNo drug interventionsprevention3completed
NCT03431675
Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018prevention4withdrawn
NCT00780806
Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In AdultsNo drug interventionsNot Available1 / 2completed
NCT05229536
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 MonthsNo drug interventionsprevention2completed
NCT03295318
Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Oldsprevention2completed
NCT00314041
Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in InfantsNo drug interventionsprevention2completed
NCT03433482
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Ageprevention2completed
NCT02878291
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 MonthsNo drug interventionsprevention1unknown_status
NCT04689191
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide VaccineNo drug interventionsprevention3unknown_status
NCT04707391
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccineprevention3completed
NCT04665791
A Human Controlled Infection Study With Neisseria Lactamica in Malian AdultsNo drug interventionsbasic_scienceNot Availableunknown_status
NCT00798304
Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy InfantsNo drug interventionsprevention2terminated
NCT00443846
RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)prevention3completed
NCT00879814
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy AdultsNo drug interventionsprevention1completed
NCT00297687
Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy AdultsNo drug interventionsprevention1completed
NCT06113198
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of AgeNo drug interventionsprevention4not_yet_recruiting
NCT00808028
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In AdolescentsNo drug interventionsprevention2completed
NCT00161928
Study of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infantsprevention3completed
NCT03824093
High and Low Resource Interventions to Promote HPV VaccinesNo drug interventionshealth_services_researchNot Availablecompleted
NCT03205371
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlersprevention3completed
NCT03587207
Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Yearsprevention2completed
NCT05087056
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy AdolescentsNo drug interventionsprevention2active_not_recruiting
NCT05252715
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 MonthsNo drug interventionsprevention3active_not_recruiting
NCT03493919
A Sourcing Study to Collect Human Blood Samples From Healthy Adultsother4completed
NCT03378258
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.No drug interventionsNot AvailableNot Availablecompleted
NCT03682939
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Populationother4unknown_status
NCT03549325
A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14No drug interventionspreventionNot Availableunknown_status
NCT00474526
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infantsprevention3completed
NCT04689165
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide VaccineNo drug interventionsprevention3unknown_status
NCT02724046
Ciprofloxacin for the Prevention of Meningococcal Meningitisprevention4completed
NCT04685850
Long-term Sequelae of Childhood Meningitis and Meningococcal Purpura FulminansNo drug interventionsNot AvailableNot Availablerecruiting